The FDA Has Approved Thermo Fisher Scientific's Immunoassay As First & Only Blood-Based Biomarker Test To Assess Preeclampsia
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved Thermo Fisher Scientific's immunoassay as the first and only blood-based biomarker test to assess preeclampsia. This approval could lead to increased demand for the company's diagnostic products.
May 19, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Thermo Fisher Scientific's immunoassay has been approved by the FDA as the first blood-based biomarker test for preeclampsia assessment, potentially increasing demand for the company's diagnostic products.
The FDA approval of Thermo Fisher Scientific's immunoassay as the first and only blood-based biomarker test for preeclampsia assessment is a significant milestone for the company. This approval could lead to increased demand for their diagnostic products, as healthcare providers may adopt this new test for preeclampsia assessment. As a result, this news is likely to have a positive short-term impact on TMO's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100